KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Net Margin (2016 - 2025)

Historic Net Margin for Halozyme Therapeutics (HALO) over the last 17 years, with Q3 2025 value amounting to 49.46%.

  • Halozyme Therapeutics' Net Margin rose 22300.0% to 49.46% in Q3 2025 from the same period last year, while for Sep 2025 it was 47.91%, marking a year-over-year increase of 64800.0%. This contributed to the annual value of 43.74% for FY2024, which is 97800.0% up from last year.
  • As of Q3 2025, Halozyme Therapeutics' Net Margin stood at 49.46%, which was up 22300.0% from 50.7% recorded in Q2 2025.
  • Over the past 5 years, Halozyme Therapeutics' Net Margin peaked at 186.99% during Q3 2021, and registered a low of 14.89% during Q2 2022.
  • For the 5-year period, Halozyme Therapeutics' Net Margin averaged around 48.89%, with its median value being 40.3% (2024).
  • Per our database at Business Quant, Halozyme Therapeutics' Net Margin surged by 1315500bps in 2021 and then plummeted by -1574900bps in 2022.
  • Over the past 5 years, Halozyme Therapeutics' Net Margin (Quarter) stood at 65.46% in 2021, then crashed by -51bps to 31.79% in 2022, then increased by 17bps to 37.12% in 2023, then rose by 24bps to 45.98% in 2024, then grew by 8bps to 49.46% in 2025.
  • Its last three reported values are 49.46% in Q3 2025, 50.7% for Q2 2025, and 44.59% during Q1 2025.